The business reported net earnings due to Bristol-Myers Squibb of $726 million, or $0.44 per share, in the quarter compared to $925 million, or $0.56 per share, a year ago. The company reported non-GAAP net earnings attributable to Bristol-Myers Squibb of $842 million, or $0.51 per share, in the fourth quarter, in comparison to $777 million, or $0.47 per share, for the same period in 2012. Cash, money equivalents and marketable securities were $8.3 billion, with a net debt position of $68 million, as of 31 December, 2013. In December, the company announced plans to sell its global diabetes business that was component of its collaboration with AstraZeneca, enabling its continued evolution to a specialty care BioPharma company. Under conditions of the agreement, AstraZeneca can make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with potential regulatory – and sales-based milestone payments as high as $1.4 billion and will make royalty payments predicated on net sales through 2025.Why are some individuals allergic for some antibiotics? Another type of antibiotic may not cause you the same problem. On average, how well-educated are people on antibiotics? NPS MedicineWise study earlier this year discovered that 1 in 5 Australians anticipate their doctor to prescribe antibiotics for themselves and/or their child when they possess a cough or chilly. Of the 1013 Australians surveyed nationwide, 4 in 5 also said a prescription is anticipated by them from their GP if they have an ear, nose, chest or throat infection, with more than fifty % saying they might ask their GP for one. The survey also uncovered a plethora of misconceptions when it comes to antibiotics with only half of respondents knowing that bacteria have become resistant to antibiotics.